Sunscreens with the New MCE Filter Cover the Whole UV Spectrum: Improved UVA1 Photoprotection In Vitro and in a Randomized Controlled Trial.
FC, fold change
ITA°, individual typology angle
KC, keratinocyte
MCE, Methoxypropylamino Cyclohexenylidene Ethoxyethylcyanoacetate
MMP, matrix metalloproteinase
SPF, sun-protection factor
Journal
JID innovations : skin science from molecules to population health
ISSN: 2667-0267
Titre abrégé: JID Innov
Pays: Netherlands
ID NLM: 101776173
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
17
05
2021
revised:
27
10
2021
accepted:
28
10
2021
entrez:
24
1
2022
pubmed:
25
1
2022
medline:
25
1
2022
Statut:
epublish
Résumé
UVA1 rays (340-400 nm) contribute to carcinogenesis, immunosuppression, hyperpigmentation, and aging. Current sunscreen formulas lack sufficient absorption in the 370-400 nm wavelengths range. Recently, a new UVA1 filter, Methoxypropylamino Cyclohexenylidene Ethoxyethylcyanoacetate (MCE) exhibiting a peak of absorption at 385 nm, was approved by the Scientific Committee on Consumer Safety for use in sunscreen products. These studies evaluated, in a three-dimensional skin model and in vivo, the protection afforded by state-of-the-art sunscreen formulations enriched with MCE. This study is a monocentric, double-blinded, randomized, and comparative trial. This study is registered at ClinicalTrials.gov with the identification number NCT04865094. The efficacy of sunscreens with MCE was compared with that of reference formulas. In a three-dimensional skin model, histology, protein, and gene expression were analyzed. In the clinical trial, pigmentation was analyzed in 19 volunteers using colorimetric measurements and visual scoring. MCE addition in reference formulas enlarged the profile of absorption up to 400 nm; reduced UVA1-induced dermal and epidermal alterations at cellular, biochemical, and molecular levels; and decreased UVA1-induced pigmentation. Addition of MCE absorber in sunscreen formulations leads to full coverage of UV spectrum and improved UVA1 photoprotection. The data support benefits in the long term on sun-induced consequences, especially those related to public health care issues.
Sections du résumé
BACKGROUND
BACKGROUND
UVA1 rays (340-400 nm) contribute to carcinogenesis, immunosuppression, hyperpigmentation, and aging. Current sunscreen formulas lack sufficient absorption in the 370-400 nm wavelengths range. Recently, a new UVA1 filter, Methoxypropylamino Cyclohexenylidene Ethoxyethylcyanoacetate (MCE) exhibiting a peak of absorption at 385 nm, was approved by the Scientific Committee on Consumer Safety for use in sunscreen products. These studies evaluated, in a three-dimensional skin model and in vivo, the protection afforded by state-of-the-art sunscreen formulations enriched with MCE.
TRIAL DESIGN
METHODS
This study is a monocentric, double-blinded, randomized, and comparative trial. This study is registered at ClinicalTrials.gov with the identification number NCT04865094.
METHODS
METHODS
The efficacy of sunscreens with MCE was compared with that of reference formulas. In a three-dimensional skin model, histology, protein, and gene expression were analyzed. In the clinical trial, pigmentation was analyzed in 19 volunteers using colorimetric measurements and visual scoring.
RESULTS
RESULTS
MCE addition in reference formulas enlarged the profile of absorption up to 400 nm; reduced UVA1-induced dermal and epidermal alterations at cellular, biochemical, and molecular levels; and decreased UVA1-induced pigmentation.
CONCLUSIONS
CONCLUSIONS
Addition of MCE absorber in sunscreen formulations leads to full coverage of UV spectrum and improved UVA1 photoprotection. The data support benefits in the long term on sun-induced consequences, especially those related to public health care issues.
Identifiants
pubmed: 35072138
doi: 10.1016/j.xjidi.2021.100070
pii: S2667-0267(21)00071-0
pmc: PMC8762479
doi:
Banques de données
ClinicalTrials.gov
['NCT04865094']
Types de publication
Journal Article
Langues
eng
Pagination
100070Informations de copyright
© 2021 The Authors.
Références
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
pubmed: 12184808
Photodermatol Photoimmunol Photomed. 2013 Apr;29(2):57-64
pubmed: 23458388
Ann Epidemiol. 2008 Aug;18(8):614-27
pubmed: 18652979
Clin Exp Dermatol. 2012 Apr;37(3):219-26
pubmed: 22277060
J Investig Dermatol Symp Proc. 2009 Aug;14(1):20-4
pubmed: 19675548
Biochem J. 1996 Jan 15;313 ( Pt 2):625-31
pubmed: 8573102
Dermatol Surg. 2016 Dec;42(12):1354-1361
pubmed: 27749441
Photodermatol Photoimmunol Photomed. 2000 Dec;16(6):245-9
pubmed: 11132126
Dev Biol. 1997 Mar 15;183(2):123-38
pubmed: 9126289
J Med Microbiol. 2003 May;52(Pt 5):403-408
pubmed: 12721316
Carcinogenesis. 1997 May;18(5):1013-20
pubmed: 9163689
JAMA Dermatol. 2014 Apr;150(4):401-6
pubmed: 24305962
Cancers (Basel). 2019 Sep 30;11(10):
pubmed: 31575057
Proc Natl Acad Sci U S A. 2010 May 11;107 Suppl 2:8962-8
pubmed: 20445093
Arch Dermatol Res. 2007 Apr;299(1):25-32
pubmed: 17256147
Ann Intern Med. 2013 Jun 4;158(11):781-90
pubmed: 23732711
Br J Dermatol. 2017 Aug;177(2):359-372
pubmed: 28220485
Br J Dermatol. 2014 Jan;170(1):157-64
pubmed: 23980934
J Am Acad Dermatol. 1995 Jan;32(1):53-62
pubmed: 7822517
J Dermatol Sci. 2018 Sep;91(3):337-340
pubmed: 30244693
Dermatology. 1995;190(4):305-8
pubmed: 7655111
Br J Dermatol. 2013 May;168(5):1120-3
pubmed: 23550734
Int J Dermatol. 2010 Jun;49(6):623-30
pubmed: 20618465
Clin Dermatol. 2016 Sep-Oct;34(5):563-70
pubmed: 27638434
Br J Dermatol. 2011 Mar;164(3):657-9
pubmed: 21375518
Photochem Photobiol Sci. 2013 Jan;12(1):54-64
pubmed: 23111621
Indian J Dermatol Venereol Leprol. 2012 Jun;78 Suppl 1:S24-30
pubmed: 22710110
J Dermatol Sci. 2010 Sep;59(3):192-7
pubmed: 20691571
Br J Dermatol. 1990 Apr;122 Suppl 35:21-8
pubmed: 2186781
Adv Exp Med Biol. 2014;810:182-91
pubmed: 25207366
Cold Spring Harb Perspect Med. 2015 Jan 05;5(1):a015370
pubmed: 25561721
PLoS One. 2014 Aug 20;9(8):e105263
pubmed: 25140898
Photochem Photobiol Sci. 2013 Jan;12(1):95-103
pubmed: 23192740
J Invest Dermatol. 2006 May;126(5):971-9
pubmed: 16528360
Photochem Photobiol Sci. 2012 Jan;11(1):207-15
pubmed: 22005748
J Invest Dermatol. 2017 May;137(5):1184-1187
pubmed: 28082185
Prog Biophys Mol Biol. 2011 Dec;107(3):362-6
pubmed: 21958910
Immunol Lett. 2003 Dec 15;90(2-3):103-22
pubmed: 14687712
Cell Death Differ. 2004 Apr;11(4):381-9
pubmed: 14685163
Photochem Photobiol. 2000 Oct;72(4):485-7
pubmed: 11045719
Front Med (Lausanne). 2018 Sep 10;5:252
pubmed: 30250845
J Invest Dermatol. 2014 Oct;134(10):2598-2609
pubmed: 24714202
Arch Dermatol Res. 2015 Jul;307(5):385-96
pubmed: 25708189
J Invest Dermatol. 2020 Dec;140(12):2478-2486.e4
pubmed: 32416083